Company Announcement - ALX Oncology granted an inducement stock option to purchase 600,000 shares of common stock to Harish Shantharam, the Chief Financial Officer, effective January 21, 2025 [1] - The stock option has an exercise price of $1.65 per share, equal to the closing price on the grant date [2] - The option vests as follows: 25% on the one-year anniversary of January 21, 2025, and an additional 1/48th monthly thereafter, contingent on continued employment [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that enhance the immune system to treat cancer and extend patient lives [3] - The company's lead therapeutic candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications [3] - Evorpacept has shown potential to serve as a cornerstone therapy in immuno-oncology [3]
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules